What is GUI-0158 version 4?
GUI-0158 is Health Canada’s official guidance on Good Manufacturing Practices for natural health products. It interprets Part 3 of the Natural Health Products Regulations (SOR/2003-196) and applies to every party in the NHP supply chain — manufacturers, packagers, labellers, importers, distributors, storage facilities and testing labs. Version 4, published by the Natural and Non-prescription Health Products Directorate (NNHPD) on September 4, 2025, is the first comprehensive rewrite since version 3 in December 2015.
The guide is administrative rather than statutory. It does not create new legal obligations. What it does is set out, in markedly more prescriptive detail than v3, how Health Canada inspectors will interpret existing regulatory requirements when they walk a site.
When does GUI-0158 v4 take effect?
GUI-0158 v4 came into force on March 4, 2026. The six-month transition period from September 4, 2025 to that date allowed companies to update systems, procedures and documentation. Version 3 was retired on the effective date and is no longer the reference standard for inspections.
Who must comply with GUI-0158 v4?
Any party conducting a licensable activity involving NHPs — manufacturing, packaging, labelling, or importing — must comply, along with distributors, storage operators, testing laboratories and product licence holders. The guide applies to non-sterile NHPs (vitamins, minerals, herbal remedies, probiotics, traditional medicines, certain toothpastes, antiperspirants and mouthwashes), sterile NHPs (ophthalmics, sterile water for irrigation) and homeopathic medicines. Retail establishments that sell directly to consumers are generally exempt from storage GMP requirements, unless they also manufacture or import.
What changed from GUI-0158 version 3 to version 4?
The most important shift is philosophical. Version 3 was organised around discrete activities — specifications, premises, equipment, personnel, sanitation — and a small operator could satisfy it by attaching an SOP to each section and keeping the binder current. Version 4 reorganises the entire guide to follow the order of Part 3 of the regulations and, crucially, anchors GMP compliance to a documented Quality Management System (QMS). The QMS is no longer implied; it is the framework into which every other obligation slots.
Concretely, v4 introduces or expands guidance on:
- Formal QMS structure, with named senior or executive management responsibility for governance and decision-making authority.
- Quality risk management, with explicit reference to ICH Q9 as a useful — though not legally binding — model.
- Stability protocols, real-time studies and ongoing stability monitoring (section 52).
- Quality agreements for outsourced GMP activities, with supplier qualification and periodic audit.
- Deviation handling, out-of-specification (OOS) investigations and CAPA effectiveness verification.
- Recall systems, including mandatory periodic mock recalls.
- Electronic records, electronic signatures and data integrity (ALCOA).
- Importer obligations for foreign-site GMP evidence and review of batch documentation.
- An updated risk classification framework that aligns observation severity with regulatory response.
Read alongside the regulator’s recent enforcement posture, GUI-0158 v4 is the most consequential GMP rewrite the NHP sector has seen since the modern site licensing regime took shape. It imports the language and discipline of pharmaceutical quality systems — ICH Q9, ALCOA, IQ/OQ equipment qualification, formal quality agreements — into a sector that has historically worked under a much looser interpretation of “adequate.” Companies that treat the transition as a paperwork refresh will be caught flat-footed when inspectors arrive.
How does GUI-0158 v4 change stability testing for NHPs?
Section 52 is where the bills land. Under version 3, stability expectations were sparse enough that many NHP companies — particularly smaller brands and private-label houses — relied on supplier letters, “similar product” data or accelerated studies alone to assign expiry. Version 4 closes the door. Every NHP marketed in Canada must now have:
- A written stability protocol specifying test parameters, time points, acceptance criteria and study design.
- A completed real-time stability study on representative lots in the actual formulation, packaging and process used for marketed product.
- A stability report, kept current as data accumulates.
- Ongoing responsibility for the data regardless of who runs the test — including importers relying on foreign studies.
Real-time data is required to confirm shelf life. Accelerated testing alone is not sufficient, particularly for heat- and humidity-sensitive products. Expiry is dated from manufacture, not packaging — which will surprise more than a few brands whose date math has drifted over time. Worst-case scenarios such as bulk hold time before fill must be captured in the protocol.
Crucially, Health Canada has also opened the door to ICH Q1D bracketing and matrixing — testing only the extreme variants of a product family, or rotating a subset across pulls — provided the science is documented. Sophisticated companies with disciplined SKU portfolios can use this provision to materially reduce lab cost. Companies whose stability data lives in scattered spreadsheets and supplier emails will find themselves quoted six-figure programmes by contract labs to backfill in time.
What does GUI-0158 v4 require of the Quality Assurance Person (QAP)?
Version 4 expands the QAP’s mandate explicitly. The QAP must approve every batch before sale, oversee documentation, manage deviations and OOS investigations, ensure data integrity, and sign off on supplier qualification and recall systems. The role has effectively been promoted from gatekeeper to quality director — without, in most small companies, a corresponding budget for headcount.
The companion change is the formal codification of senior management responsibility. Executive leadership must demonstrably participate in the QMS: defining roles, allocating resources, reviewing quality metrics and acting on internal audit findings. Inspectors will look for management review minutes and documented decisions, not after-the-fact attestations. The hiring market is the leading indicator here — demand for QAPs with pharma-grade quality-systems experience is already tight.
What are the new quality-agreement rules for contract manufacturing?
The Canadian NHP supply chain is heavily outsourced. Brands without their own facility rely on a relatively small set of domestic contract manufacturers (CMOs) and a larger network of foreign sites. Under v3, written quality agreements were good practice; under v4, they are an explicit expectation for every outsourced GMP activity — manufacturing, packaging, labelling, testing or storage — and must allocate clear responsibilities for recordkeeping, deviations, change control, complaint investigations and recalls.
The contracting party must also be able to show how it qualifies contractors and audits them periodically. “We trust them” is no longer a defensible answer. Expect a wave of quality-agreement renegotiations, with CMOs pushing back on liability allocation and brand owners discovering that their long-standing master services agreements do not address half of what v4 contemplates. Smaller brands that cannot stand up the contract-giver oversight v4 demands will be pushed toward CMOs that effectively run the QMS for them — accelerating a consolidation dynamic that has been building in the sector for several years.
How does GUI-0158 v4 affect NHP importers and foreign sites?
The clarified obligations on importers are easy to miss but consequential. Importers must hold current and complete GMP evidence — audit reports, certificates from qualified authorities, quality agreements — for every foreign site in their supply chain. The Foreign Site Reference Number (FSRN) is useful for streamlining submissions but does not substitute for the importer’s responsibility to verify foreign GMP compliance.
In practical terms, v4 lets Health Canada reach foreign manufacturing through the Canadian importer’s recordkeeping. Importers can expect requests for current evidence at inspection or licence renewal, and pleading reliance on a counterparty’s representations will not suffice. For companies bringing in ingredients or finished NHPs from the United States, India, China or the European Union, this is the most material change in how international supply chains will be governed under Canadian law.
What does GUI-0158 v4 say about electronic records and data integrity?
Version 4 introduces explicit expectations on electronic records, signatures and data integrity, citing the ALCOA principles — data must be attributable, legible, contemporaneous, original and accurate. Electronic systems must be validated or qualified with audit trails, access controls and backups. Electronic signatures must be uniquely assigned, secure and traceable to the individual who signed.
For pharma-adjacent operations this is familiar territory. For much of the NHP sector — where batch records still live in Excel workbooks without version control, balance printouts are pasted into paper binders and ERP “approvals” are emailed confirmations — it is a substantial uplift. The cost is not just software. It is computer-system validation, IT change control, periodic review and the training to use the systems as designed.
Mock recalls, CAPA effectiveness and the new risk classification
Three smaller changes round out the picture. Mock recalls are now explicitly required on a periodic basis to confirm traceability works in the time the regulator expects. CAPA effectiveness — not just CAPA closure — must be verified and documented; closing a corrective action without evidence that it prevented recurrence is, under v4, an open finding. And the risk classification framework that inspectors apply has been refreshed to better align severity with response, which means companies should expect more consistent — and in some categories more aggressive — enforcement outcomes than the v3-era variability.
What has changed since March 4, 2026?
Three months into enforcement, the picture of how Health Canada is operationalising v4 is becoming clearer.
The pre-inspection package has been refreshed. Health Canada’s NHP GMP pre-inspection package was updated on April 24, 2026, and now sits openly on Canada.ca as the operational companion to GUI-0158 v4. It includes activity-specific checklists for manufacturers, packagers, labellers and importers, an explicit list of documents an inspector will request before arriving, and a clean restatement of the inspection flow: opening meeting, premises tour, assessment, documentation review, closing meeting, exit notice. The package pins down the CAPA timelines that had been inconsistent under v3 — 20 business days for a compliant inspection, 90 calendar days for non-compliant, with CAPA required for risk 1 and risk 2 observations.
Inspection results are now public. Following an October 29, 2025 bulletin, NHP inspection outcomes are published on the Drug and Health Products Inspection Database alongside drug-side results. For a sector that has historically managed regulatory friction privately, this imports the reputational dynamics of pharma compliance: a non-compliant rating is no longer a quiet exchange of letters, it is a public record that retailers, listing platforms and acquirers will read.
The broader NHP modernisation agenda continues to move. Health Canada updated 11 NHP monographs in March 2026, and a refreshed plain-language labelling proposal advanced through stakeholder consultation in April and May. Neither item is a GMP change, but both reinforce the same direction of travel: the NHP regulatory perimeter is tightening on multiple fronts at once.
Early industry signals point to four recurring gaps. The Canadian Health Food Association (CHFA) has flagged four areas as the most common weaknesses members are reporting in early v4 inspections: translation of GMP records into English or French where applicable, validation of electronic quality and laboratory systems, importer evidence packages for foreign sites, and the operational maturity of mock recall programmes.
How should NHP companies prepare for a GUI-0158 v4 inspection?
There is no version of v4 that can be implemented in the last six weeks before a licence renewal. A realistic readiness plan covers six layers:
- Gap assessment. Map current SOPs, master production documents, batch records and QA release processes against the new GUI-0158 v4 section structure. Score each gap by risk classification (1, 2 or 3).
- QMS uplift. Document the quality management system, including senior-management responsibilities, management review cadence and quality metrics.
- Stability remediation. Confirm every marketed SKU has a written protocol, real-time data and a current stability report. Apply ICH Q1D bracketing/matrixing where scientifically defensible.
- Supplier and contractor controls. Renew quality agreements with all CMOs, ingredient suppliers and testing labs. Schedule periodic audits.
- Data integrity. Validate or qualify electronic systems handling GMP data; implement audit trails, access controls and backup. Train staff on ALCOA.
- Mock inspection and mock recall. Run both in the quarter before licence renewal. Close findings before they become real ones.
The deeper point — and one the trade press has been slow to articulate — is that GUI-0158 v4 ends the long ambiguity about what Canadian GMP for natural health products actually looks like. It looks, increasingly, like junior pharma: documented quality systems, named accountability, validated systems, justified science. Companies that meet the bar will operate more efficiently and defensibly across borders. Companies that do not will find their next inspection a much harder day than the regulator’s measured language suggests — now with the added pressure of a public scoreboard.
Frequently asked questions about GUI-0158 v4
When did GUI-0158 v4 take effect?
GUI-0158 version 4 came into force on March 4, 2026. Health Canada published the guide on September 4, 2025, with a six-month transition period during which version 3 (December 2015) remained in use.
Does GUI-0158 v4 change the underlying Natural Health Products Regulations?
No. GUI-0158 v4 is guidance, not regulation. The legal requirements remain in Part 3 of the Natural Health Products Regulations. The new guide clarifies how Health Canada expects those requirements to be implemented and evidenced during inspection.
Are accelerated stability studies still acceptable under GUI-0158 v4?
Accelerated data alone is not sufficient to justify a shelf life. Section 52 requires a completed real-time study, a written stability protocol and a stability report for every NHP marketed in Canada. ICH Q1D bracketing and matrixing are permitted when scientifically justified.
Can importers rely on a Foreign Site Reference Number (FSRN) instead of GMP evidence?
No. The FSRN can streamline submissions but does not replace the importer’s obligation to hold current and complete GMP evidence — audit reports, certificates from qualified authorities and quality agreements — for every foreign manufacturing, packaging, labelling, testing or storage site.
Is a written quality agreement mandatory with a contract manufacturer?
Yes. GUI-0158 v4 expects a written quality agreement for every outsourced GMP activity, allocating responsibility for recordkeeping, deviations, change control, complaint investigations and recalls. The contract-giver must also demonstrate processes to qualify and periodically audit contractors.
What is the CAPA submission timeline after an NHP GMP inspection?
Per Health Canada’s NHP GMP pre-inspection package (updated April 24, 2026), CAPA plans are due 20 business days after a compliant inspection or 90 calendar days after a non-compliant inspection. A CAPA plan is required for risk 1 and risk 2 observations.
Are NHP inspection results published?
Yes. Following Health Canada’s October 29, 2025 bulletin, NHP inspection outcomes are published on the Drug and Health Products Inspection Database alongside drug-side inspection results.
Does GUI-0158 v4 require electronic batch records?
GUI-0158 v4 does not mandate electronic records. Where they are used, the systems must be validated or qualified with audit trails, access controls and backups, and the data must meet ALCOA principles — attributable, legible, contemporaneous, original and accurate.
Sources and further reading
Health Canada. Good manufacturing practices guide for natural health products (GUI-0158), Version 4 (in force March 4, 2026).
Health Canada. GUI-0158 version 4: Notice (September 4, 2025).
Health Canada. NHP good manufacturing practices pre-inspection package (modified April 24, 2026).
Health Canada NNHPD. Bulletin on publishing NHP inspection results on the Drug and Health Products Inspection Database (October 29, 2025).
Gowling WLG. Health Canada updates GMP guidance for natural health products (September 25, 2025).
Canadian Health Food Association. Member advisory on GUI-0158 v4.
Source Nutraceutical Inc. What’s New in Version 4.0 and How to Comply (September 2025).
Certified Laboratories. NHP GMPs 4.0: Stability Testing FAQs (October 2025).
Broughton. Health Canada’s updated GMP guidance for NHPs: what changes in practice from March 2026 (April 2, 2026).
